202 related articles for article (PubMed ID: 37189724)
1. VP37 Protein Inhibitors for Mpox Treatment: Highlights on Recent Advances, Patent Literature, and Future Directions.
Hudu SA; Alshrari AS; Al Qtaitat A; Imran M
Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189724
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis.
Shamim MA; Satapathy P; Padhi BK; Veeramachaneni SD; Akhtar N; Pradhan A; Agrawal A; Dwivedi P; Mohanty A; Pradhan KB; Kabir R; Rabaan AA; Alotaibi J; Al Ismail ZA; Alsoliabi ZA; Al Fraij A; Sah R; Rodriguez-Morales AJ
Front Pharmacol; 2023; 14():1149909. PubMed ID: 37214444
[TBL] [Abstract][Full Text] [Related]
3. Emerging pharmacological strategies for treating and preventing mpox.
Grosenbach DW; Russo AT; Blum ED; Hruby DE
Expert Rev Clin Pharmacol; 2023; 16(9):843-854. PubMed ID: 37592723
[TBL] [Abstract][Full Text] [Related]
4. The discovery of novel antivirals for the treatment of mpox: is drug repurposing the answer?
Ezat AA; Abduljalil JM; Elghareib AM; Samir A; Elfiky AA
Expert Opin Drug Discov; 2023 May; 18(5):551-561. PubMed ID: 37032577
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf.
De Clercq E; Jiang Y; Li G
Travel Med Infect Dis; 2023; 52():102528. PubMed ID: 36539022
[TBL] [Abstract][Full Text] [Related]
6. Repurposing of the antibiotic nitroxoline for the treatment of mpox.
Bojkova D; Zöller N; Tietgen M; Steinhorst K; Bechtel M; Rothenburger T; Kandler JD; Schneider J; Corman VM; Ciesek S; Rabenau HF; Wass MN; Kippenberger S; Göttig S; Michaelis M; Cinatl J
J Med Virol; 2023 Mar; 95(3):e28652. PubMed ID: 36897017
[TBL] [Abstract][Full Text] [Related]
7. Antivirals With Activity Against Mpox: A Clinically Oriented Review.
Siegrist EA; Sassine J
Clin Infect Dis; 2023 Jan; 76(1):155-164. PubMed ID: 35904001
[TBL] [Abstract][Full Text] [Related]
8. Potential therapeutic targets for Mpox: the evidence to date.
Byrareddy SN; Sharma K; Sachdev S; Reddy AS; Acharya A; Klaustermeier KM; Lorson CL; Singh K
Expert Opin Ther Targets; 2023; 27(6):419-431. PubMed ID: 37368464
[TBL] [Abstract][Full Text] [Related]
9. Clinical considerations on monkeypox antiviral medications: An overview.
Pourkarim F; Entezari-Maleki T
Pharmacol Res Perspect; 2024 Feb; 12(1):e01164. PubMed ID: 38149674
[TBL] [Abstract][Full Text] [Related]
10. A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak.
Almehmadi M; Allahyani M; Alsaiari AA; Alshammari MK; Alharbi AS; Hussain KH; Alsubaihi LI; Kamal M; Alotaibi SS; Alotaibi AN; Aldhafeeri AA; Imran M
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146675
[TBL] [Abstract][Full Text] [Related]
11. Preventing monkeypox outbreaks: Focus on diagnosis, care, treatment, and vaccination.
Ghaseminia M
J Clin Transl Sci; 2023; 7(1):e60. PubMed ID: 37008622
[TBL] [Abstract][Full Text] [Related]
12. Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential.
Russo AT; Grosenbach DW; Honeychurch KM; Long PG; Hruby DE
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):235-242. PubMed ID: 36728515
[TBL] [Abstract][Full Text] [Related]
13. Interim Clinical Treatment Considerations for Severe Manifestations of Mpox - United States, February 2023.
Rao AK; Schrodt CA; Minhaj FS; Waltenburg MA; Cash-Goldwasser S; Yu Y; Petersen BW; Hutson C; Damon IK
MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(9):232-243. PubMed ID: 36862595
[TBL] [Abstract][Full Text] [Related]
14. Antivirals for the treatment of Monkeypox: utilization in the general and HIV-positive population and gaps for research. A short narrative review.
Ivanov DT; Slabakova YA; Argirova RM; Valkov TK
Infez Med; 2023; 31(2):186-194. PubMed ID: 37283638
[TBL] [Abstract][Full Text] [Related]
15. Trifluridine for treatment of mpox infection in drug combinations in ophthalmic cell models.
Cinatl J; Bechtel M; Reus P; Ott M; Rothweiler F; Michaelis M; Ciesek S; Bojkova D
J Med Virol; 2024 Jan; 96(1):e29354. PubMed ID: 38180134
[TBL] [Abstract][Full Text] [Related]
16. Patent profile for the approved and in clinical trials Mpox vaccines.
der Weid IV; de Souza Mendes CD; Fonseca PC; Viveiros Rosa SG
Pharm Pat Anal; 2023 May; 12(3):103-111. PubMed ID: 37671905
[TBL] [Abstract][Full Text] [Related]
17. Breaking Barriers: Current Advances and Future Directions in Mpox Therapy.
Shah BM; Modi P
Curr Drug Targets; 2024; 25(1):62-76. PubMed ID: 38151842
[TBL] [Abstract][Full Text] [Related]
18. Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report.
Martinez AE; Frattaroli P; Vu CA; Paniagua L; Mintz J; Bravo-Gonzalez A; Zamudio P; Barco A; Rampersad A; Lichtenberger P; Gonzales-Zamora JA
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992234
[TBL] [Abstract][Full Text] [Related]
19. Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments.
Akazawa D; Ohashi H; Hishiki T; Morita T; Iwanami S; Kim KS; Jeong YD; Park ES; Kataoka M; Shionoya K; Mifune J; Tsuchimoto K; Ojima S; Azam AH; Nakajima S; Park H; Yoshikawa T; Shimojima M; Kiga K; Iwami S; Maeda K; Suzuki T; Ebihara H; Takahashi Y; Watashi K
J Infect Dis; 2023 Aug; 228(5):591-603. PubMed ID: 36892247
[TBL] [Abstract][Full Text] [Related]
20. Mpox (monkeypox): Diagnosis, prevention, and management in adults.
Jarrell L; Perryman K
Nurse Pract; 2023 Apr; 48(4):13-20. PubMed ID: 36975744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
